AUPH files 8‑K with Q3 2025 earnings release and update

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.

The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001600620FALSE00016006202025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

Aurinia Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Canada

001-36421

98-1231763

(State or Other Jurisdiction of Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

#140, 14315 - 118 Avenue

Edmonton, Alberta

T5L 4S6

(250) 744-2487

(Address and telephone number of registrant's principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Shares, without par value

AUPH

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02 Results of Operations and Financial Condition

On November 4, 2025, Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.						Description
99.1						Earnings release dated November 4, 2025
99.2						Aurinia's Third Quarter 2025 Update dated November 4, 2025
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2025

						AURINIA PHARMACEUTICALS INC.
			By:			/s/ Joseph Miller
			Name:			Joseph Miller
			Title:			Chief Financial Officer

FAQ

What did Aurinia (AUPH) announce in this 8‑K?

Aurinia furnished a press release announcing financial results for the quarter ended September 30, 2025, along with a Third Quarter 2025 Update.

Which exhibits are included with AUPH’s 8‑K?

Exhibit 99.1 is the earnings release dated November 4, 2025 and Exhibit 99.2 is Aurinia’s Third Quarter 2025 Update. Exhibit 104 covers the cover page Inline XBRL tags.

Is the earnings information considered “filed” with the SEC?

No. The information furnished under Item 2.02 is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.

What period do the results cover for AUPH?

The results cover the quarter ended September 30, 2025.

Who signed the 8‑K for Aurinia?

Chief Financial Officer Joseph Miller signed the report on November 4, 2025.

What is Aurinia’s trading symbol and exchange?

Aurinia’s common shares trade on The Nasdaq Stock Market LLC under the symbol AUPH.